19 May 2013
Keywords: b-ms, ipilimumab, doubles, one-year, survival, advanced, melanoma
Article | 22 September 2008
US drug major Bristol-Myers Squibb presented data from three mid-stage trials in advanced melanoma showing that half of patients on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 September 2008
17 May 2013
© 2013 thepharmaletter.com